☆ 4.7 Meeting Abstract

Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 40, Issue 6, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2022.40.6_suppl.338

Keywords

Funding

Eisai Inc., Woodcliff Lake, NJ, USA
Merck Sharp Dohme Corp.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

Categories

Funding

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper